April 23, 2014 8:50 PM ET

Pharmaceuticals

Company Overview of Virobay Inc.

Company Overview

Virobay Inc. engages in the design, synthesis, and development of small molecule inhibitors of cysteine proteases for the treatment of autoimmune diseases, neuropathic pain, liver diseases, and cancer. It offers VBY-129, VBY-891, VBY-036, VBY-285, VBY-376, VBY-825 inhibitors against cathespin protease, liver fibrosis, atherosclerosis, cardiovascular disorders, and other disease indications. Virobay Inc. was founded in 2006 and is headquartered in Menlo Park, California with contract research and manufacturing facilities worldwide.

1490 O’Brien Drive

Suite G

Menlo Park, CA 94025

United States

Founded in 2006

Phone:

650-833-5700

Fax:

650-833-6892

Key Executives for Virobay Inc.

Co-Founder
Age: 59
Co-Founder and Director
Age: 47
Vice President of Project Management & Operations
Chief Medical Officer
Vice President of Biology
Compensation as of Fiscal Year 2013.

Virobay Inc. Key Developments

Virobay Inc. Initiates Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain

Virobay Inc. announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor. The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults. The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay. Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year. VBY-891 is being developed in partnership with LEO Pharma for the therapy of dermatological diseases.

Virobay Inc. Presents at BioEquity Europe 2013, May-22-2013 06:00 PM

Virobay Inc. Presents at BioEquity Europe 2013, May-22-2013 06:00 PM. Venue: Sheraton Stockholm, Stockholm, Sweden.

Virobay Inc. and LEO Pharma A/S Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

Virobay Inc. and LEO Pharma A/S announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor. The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.

Similar Private Companies By Industry

Company Name Region
Sky Growth Acquisition Corporation United States
Ally Pharma US, Inc. United States
Genoa Pharmaceuticals, Inc. United States
Pecos Labs Inc. United States
Warner Chilcott Company, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Virobay Inc., please visit www.virobayinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.